FDA, Merck, and Vioxx, putting patient safety first?
Subtitle: hearing before the Committee on Finance, United States Senate, One Hundred Eighth Congress, second session, November 18, 2004
Series: S. hrg -- 108-791; Hein's electronic documents reprint series -- title 33; Hein's electronic documents reprint series -- title 33.
Publisher: William S. Hein.
Published: 2012
Place of publication: Buffalo, N.Y
Language: eng
Number of pages: 971
Subjects: Drugs; Law and legislation; Rofecoxib; Corrupt practices; Drug monitoring; Testing; Merck & Co
Notes: Reprint of a congressional hearing. Original version withdrawn in 2006 by the U.S. Government Printing Office before distribution to depository libraries.

Includes bibliographical references.

Statements of committee chairs and testimony of expert witnesses also available via Internet from the GPO permanent archive. Address as of 10/25/06: http://permanent.access.gpo.gov/lps75299/merckvioxx.pdf; current access available via PURL.